Skip to content

Erasca, Inc. ERAS Operating Cash Flow

Operating Cash Flow at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$1.1B-43.5%
Eli Lilly logo
Eli LillyLLY
$5.33B+220%
Pfizer logo
PfizerPFE
$2.62B+12.0%
Amgen logo
AmgenAMGN
$2.19B+57.4%
Revolution Medicines, Inc. logo
Revolution Medicines, Inc.RVMD
-$354.17M-82.2%
Tango Therapeutics logo
Tango TherapeuticsTNGX
-$44.36M-6.4%

Other financials

Income statement

See full
Operating income-$187.9M-427%
Net income-$183.4M-492%
EPS (diluted)-$0.60-445%

Balance sheet

See full
Cash & equivalents$47.3M-33.0%
Total debt$46.0M-9.6%
Total equity$393.5M-1.5%
Total assets$461.2M-2.1%

Cash flow

See full
CapEx$36.0K-56.6%
Free cash flow-$27.4M+13.3%

Valuation

See full
Market cap$4.25B+1,196%
Enterprise value$4.25B+1,265%

Returns & leverage

See full
Return on equity-69.9%+77.1pp
Debt / equity0.1×0.0×
Current ratio9.5×-2.8×

Where this comes from

Reported directly by Erasca, Inc. in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.

The official record: Erasca, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Erasca, Inc.'s operating cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Erasca, Inc.'s operating cash flow?
Erasca, Inc. (ERAS) reported operating cash flow of -$27.38M in Q1 2026.
How has Erasca, Inc.'s operating cash flow changed year-over-year?
Erasca, Inc.'s operating cash flow increased by 13.2% year-over-year, from -$31.56M to -$27.38M.
What is the long-term trend for Erasca, Inc.'s operating cash flow?
Over 4 years (2021 to 2025), Erasca, Inc.'s operating cash flow has grown at a 4.6% compound annual growth rate (CAGR), from -$79.6M to -$95.46M.
What does operating cash flow mean?
Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.